Session Chair Profile

PHD, Advisory Board, Alnylam Scientific

Biography
Dr. John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021. He continues to serve on the Alnylam Scientific Advisory Board. Prior to Alnylam, he was at Millennium Pharmaceuticals, Inc., before Millennium, he held scientific and business roles at Biogen, Inc. Previously, he was a scientist at ZymoGenetics, Inc. and the Upjohn Company. He is currently a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, an Executive Partner at RTW Investments, and Senior Advisor for Blackstone Life Sciences. He is also member of the Board of Directors for Agios Pharmaceuticals, Beam Therapeutics, Kymera Therapeutics, ProKidney Corp., Takeda Pharmaceuticals, Aerium, Hemab, Aera, and Versanis, and the Biotechnology Innovation Organization. In addition, he serves on the Board of the Termeer Foundation and as Chair of the n-Lorem Foundation Advisory Council on the Advisory Board of Ariadne Labs and as an advisor to Nucleate.


 Session Abstract – PMWC 2023 Silicon Valley


Track 1, January 25

Track Co-Chairs:
Yael Weiss, Mahzi
Peter Marks, FDA

  • Welcome and Opening by Track Chairs: Yael Weiss, Mahzi & Peter Marks, FDA
  • Patient Driven Therapies: The Challenges and Successes (PANEL)
    Chair: Yael Weiss, Mahzi
    - Allyson Berent, Angelman Foundation
    - Terry Pirovolakis, CureSPG50
  • From Bench to Bedside - Biomarkers, Natural History Studies, Animal Models (PANEL)
    Chair: Peter Marks, FDA
    - Emil Kakkis, Ultragenyx
    - Alysson Muotri, UCSD
    - Nasha Fitter, Invitae
  • Commercialization - Moving from Rare to Common (PANEL)
    Chair: John Maraganore, Alnylam Pharmaceuticals
    - Shankar Ramaswamy, Kriya
    - Rahul Singhvi, Resilience
    - Andrew Lo, MIT
    - Mark Harrison, University of British Colombia
  • Future Modalities (PANEL)
    Chair: Shannon Muir, CIAPM
    - Nadav Ahituv, UCSF
  • Bioethics & Ethical Implications in Cell and Gene Therapies
    - Hank Greely, Stanford